Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel

(2015) Edurne Arriola et al.   Future Oncology

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker

(2013) Mario E Lacouture et al.   Expert Review of Anticancer Therapy

Diarrhea associated with afatinib: an oral ErbB family blocker

(2013) James Chih-Hsin Yang et al.   Expert Review of Anticancer Therapy

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) S. Peters et al.   ANNALS OF ONCOLOGY

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

(2012) A. Inoue et al.   ANNALS OF ONCOLOGY

Sodium Bicarbonate Solution versus Chlorhexidine Mouthwash in Oral Care of Acute Leukemia Patients Undergoing Induction Chemotherapy: A Randomized Controlled Trial

(2012) So-Eun Choi et al.   Asian Nursing Research

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

(2012) Ji-Youn Han et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Encouraging data out of the 2010 Congress of the European Society for Medical Oncology with respect to non-small-cell lung cancer

(2011) V. Hirsh   Current Oncology

Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer

(2011) V. Hirsh   Current Oncology

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

(2011) Vicki Leigh Keedy et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion

(2010) K. Potthoff et al.   ANNALS OF ONCOLOGY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regimen-related gastrointestinal toxicities in cancer patients

(2010) Stephen T Sonis   Current Opinion in Supportive and Palliative Care

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

(2009) Amir Harandi et al.   Journal of Oncology